MedTrace Logo

SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)

NCT05689619 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-12-15

No results posted yet for this study

Summary

This study aims to evaluate the efficacy of silibinin in preventing recurrence in the brain after complete resection of a brain metastasis (BM) from non-small-cell lung cancer (NSCLC) or breast cancer (BC).

Conditions

  • Brain Metastases, Adult
  • Non Small Cell Lung Cancer
  • Breast Cancer

Interventions

DIETARY_SUPPLEMENT

Silibinin

Silibinin 1 g/day taken orally plus standard systemic therapy for NSCLC or BC

OTHER

Placebo

Placebo 1 g/day taken orally plus standard systemic therapy for NSCLC or BC

Sponsors & Collaborators

  • A.O.U. Città della Salute e della Scienza

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2025-09-01
Completion
2027-09-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05689619 on ClinicalTrials.gov